Shikiar Asset Management Inc. Has $400,000 Position in Novo Nordisk A/S (NYSE:NVO)

Shikiar Asset Management Inc. lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 94.0% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 5,760 shares of the company's stock after selling 90,399 shares during the period. Shikiar Asset Management Inc.'s holdings in Novo Nordisk A/S were worth $400,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in NVO. Center for Financial Planning Inc. grew its holdings in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL boosted its stake in Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after buying an additional 300 shares in the last quarter. Park Square Financial Group LLC bought a new stake in Novo Nordisk A/S in the 4th quarter valued at $29,000. Transce3nd LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $33,000. Finally, Kelly Lawrence W & Associates Inc. CA bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth about $39,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 0.4%

Shares of NYSE NVO traded down $0.32 during mid-day trading on Thursday, hitting $74.03. The company's stock had a trading volume of 5,456,477 shares, compared to its average volume of 7,077,971. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The company's fifty day simple moving average is $67.98 and its 200-day simple moving average is $79.17. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The stock has a market cap of $332.19 billion, a price-to-earnings ratio of 21.90, a price-to-earnings-growth ratio of 1.33 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The company had revenue of $11.87 billion during the quarter. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on NVO shares. Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. BNP Paribas began coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating for the company. Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Finally, BMO Capital Markets reissued a "market perform" rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.